Stocks-NTLA-Intellia Therapeutics Inc

NTLA Intellia Therapeutics Inc

0 0 (0%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Trade

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2022: Intellia Therapeutics Inc's revenues increased by 57.69% and amounted to 52.12M. Net income decreased by 77.01% to -474.19M. Net assets increased by 18.78% to 1.24B and EPS decreased from -3.78 to -6.16.
NTLA's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
83.50%
Net Profit Margin
-545.66%
Operating Margin
-937.87%
Return On Investment
-29.64%